Celldex Therapeutics, Inc. Shares Fall Following Study Update; Celldex Called Buying Opportunity After Data Snafu

Published: May 21, 2010

NEW YORK, May 21 (Reuters) - Industry analysts said a selloff of Celldex Therapeutics Inc (CLDX.O) shares was caused by misinterpretation of favorable data from a study of its experimental brain cancer drug, creating a buying opportunity for investors.

Back to news